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Abstract
Inflammatory bowel disease (IBD) is a condition of chronic inflammatory
intestinal disorder with increasing prevalence but limited effective therapies.
The purine metabolic pathway is involved in various inflammatory processes
including IBD. However, the mechanisms through which purine metabolism
modulates IBD remain to be established. Here, we found that mucosal
expression of genes involved in the purine metabolic pathway is altered in
patients with active ulcerative colitis (UC), which is associated with elevated
gene expression signatures of the group 3 innate lymphoid cell (ILC3)–
interleukin (IL)-22 pathway. In mice, blockade of ectonucleotidases
(NTPDases), critical enzymes for purine metabolism by hydrolysis of
extracellular adenosine 50-triphosphate (eATP) into adenosine, exacerbates
dextran-sulfate sodium-induced intestinal injury. This exacerbation of colitis is
associated with reduction of colonic IL-22-producing ILC3s, which afford
essential protection against intestinal inflammation, and is rescued by
exogenous IL-22. Mechanistically, activation of ILC3s for IL-22 production is
reciprocally mediated by eATP and adenosine. These findings reveal that the
NTPDase-mediated balance between eATP and adenosine regulates ILC3 cell
function to provide protection against intestinal injury and suggest potential
therapeutic strategies for treating IBD by targeting the purine–ILC3 axis.
INTRODUCTION
The purinergic signaling pathway plays essential roles in
physiological and pathophysiological processes in a variety
of organs. An incompetent purine metabolic pathway has
been identified to be associated with excessive inflammation
and inappropriate resolution in numerous human
inflammatory diseases, including inflammatory bowel
disease (IBD), ischemia, diabetes and cancer.1-3 Extracellular
nucleotides such as extracellular adenosine 50-triphosphate
(eATP) that are released during tissue damage can drive
intestinal inflammation by acting as a damage-associated
molecular pattern.4,5 Cell-surface ectonucleotidases
(NTPDases) such as NTPDase1 (i.e. CD39), together with
the ecto-50-nucleotidase CD73, hydrolyze eATP to
adenosine, a purine nucleoside with anti-inflammatory
effects.3,6,7 NTPDase1 is present at high levels in intestinal
tissues from patients with IBD.8 Furthermore, gene
polymorphisms of ENTPD1 link to the human immune
system under homeostatic and inflammatory conditions
(e.g. IBD).9,10 These lines of evidence suggest that the
control of purine metabolism is important in IBD.
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Recent studies have highlighted that the metabolism of
purine nucleotides by NTPDases has a direct role in
modulation of regulatory T cells (Tregs) and interleukin
(IL)-17-producing Th17 cell functions,11-13 both important
in the genesis of pathogenic T-cell responses that form the
characteristic of IBD.14 Interestingly, a further subset of
immune cells, group 3 innate lymphoid cells (ILC3s), has
also been shown to play a major role in gut mucosal
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immunity and inflammation.15-17 ILC3s are
a group of lymphocytes without T-cell-specific antigen
receptors with particular accumulation at mucosal sites
and serve as key regulators during intestinal
inflammation.18-21 ILC3s can rapidly respond to external
stimuli and play critical roles in host defense, the
resolution of inflammation and initiation of tissue repair
in the gut.21-26 These protective effects of ILC3s are mostly
dependent on their production of the reparative cytokine
IL-22. By binding to its receptor on epithelial cells, IL-22
contributes to production of antimicrobial peptides and
mucins, regulation of gut microbiota, maintenance of the
gut barrier function and amelioration of intestinal
inflammation.25,26 But it remains unclear how ILC3s are
activated and regulated during intestinal inflammation.
Here, we have explored whether the purine pathway
signals modulate ILC3 function and whether this is
involved in regulation of intestinal injury in the animal
model. We have also investigated whether alterations in
purine metabolism are associated with activation of the
ILC3-IL-22 axis in human inflamed colon biopsies by
analyzing expression profiles. Our results demonstrate that
targeting purine metabolism and innate lymphocytes
would benefit developing new therapies against
inflammatory diseases such as IBD.
RESULTS
Alterations in purine metabolism correlate with the
ILC3/Th17-IL-22 pathway in human inflamed colon
We analyzed the gene expression profiles of whole colonic
mucosal biopsies from patients with active or inactive
ulcerative colitis (UC) and control individuals by re-
analyzing a public microarray dataset,27 with a particular
interest in the purine metabolic pathway (Figure 1a). We
found that expression of genes related to the ATP
degradation pathway was altered in inflamed colons
compared to unaffected areas of the colon and in colons of
individuals without IBD. For example, NTPDase genes (e.g.
ENTPD1,3,7) were upregulated in active UC colons
compared to inactive UC or control colons (Figure 1b),
while adenylate kinase genes (e.g. AK1-3) and nucleoside-
diphosphate kinase genes (NDPK, e.g. NME2, PCK1/2) that
catalyze the interconversion of adenine nucleotides to ATP
were downregulated in active UC colon biopsies compared
to inactive or normal control colon biopsies (Figure 1b).
While genes PNP and XDH were differentially expressed in
active UC colon, expression of 50-nucleotidase genes (e.g.
NT5E) and other ATP metabolism related genes (e.g.
AMPD, APRT, ADK, ADSS, ADSL) were not changed
among colons with different states (Figure 1b and data not
shown). Although adenosine deaminase gene expression was
upregulated, expression of DPP4 gene, encoding the
dipeptidylpeptidase IV (CD26) that directly interacts with
and controls adenosine deaminase activity,28 was
downregulated in active UC colons (Figure 1b), suggesting
that active UC colons unlikely display effective deamination
of adenosine. Moreover, expression of ADORA2A (encoding
adenosine receptor A2A), rather than other adenosine
receptors, is upregulated in actively inflamed colon biopsies
(Figure 1). These results indicate that there may be
downregulated ATP levels but enhanced adenosine signaling,
probably through the A2A receptor, in inflamed colons.
We also observed that expression of ILC3 and Th17
genes29-31 distinguished active UC from inactive UC and
controls although there were a few patient-to-patient
variations in the gene expression levels within the active
UC group (Supplementary figures 1, 2). For example,
human ILC3 genes (e.g. IL7R, NRP1, KIT), Th17 genes
(e.g. IL23A, IL17A, IL17F) and ILC3/Th17 co-expressing
genes (e.g. CCR6 and IL22) were upregulated in colon
biopsies from active UC patients compared to controls
(Figure 1c). Importantly, inflamed colons developed a
strong IL-22 response32 marked by the overexpression of
genes related to activation of IL-22 receptor signaling (e.g.
STAT3, REG3A, S100A8, MUC1, CXCL5) in active UC
colons compared to inactive UC or control colons
(Figure 1d). These results are consistent with a previous
study showing that IBD patients have more IL-22-
producing ILC3s in colonic mucosa than control
individuals.33 Interestingly, in the mucosal tissue of inflamed
Figure 1. Alterations in purine metabolism and IL-22 response in patients with intestinal inflammation. (a) Schematic depicting the purine metabolic
pathway and enzymes involved. (b) Expression of enzymes involved in purine metabolism and adenosine receptors in colonic mucosal biopsies of
patients suffering from active ulcerative colitis (UC) (n = 72), inactive UC (n = 23) or controls with normal mucosa (n = 11) as described.27 (c)
Expression of selected human ILC3 and Th17 related genes. (d) Volcano plot for changes in expression of IL-22 signaling-responsive genes in colonic
mucosal biopsies with active UC as compared to those in colonic mucosal biopsies from normal controls or with inactive UC. Each point represents
one single probe. Genes were considered biologically relevant and statistically significant with fold-change (FC) ≥ 1.4 and P ≤ 0.01, respectively. (e)
Correlations between ADORA2A with ENTPD1 expression and their correlations with ILC3 genes IL7R and NRP1 in colonic biopsy samples from
patients with active or inactive UC or controls. Microarray data were retrieved from the Gene Expression Ominibus dataset GSE5907127 and the
z-score transformed values (by gene across samples) of microarray gene expression data are shown as box and whiskers with 5–95 percentiles.
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by a nonparametric Kruskal–Wallis test with post hoc Dunn’s multiple comparisons test (b, c).
A nonparametric Spearman correlation test was performed and each point represents an individual subject (e).
◂
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colons there was a positive correlation between expression of
ENTPD1 and ADORA2A genes, and both genes positively
correlated with ILC3-signature genes (e.g. IL7R and NRP1)
in active UC colon biopsies (Figure 1e). To determine
whether these findings are unique to this population we
investigated another independent cohort.34 In this
independent investigation we also found similar pattern of
expression, particularly, the overexpression of ENTPD1 and
ADORA2A and alterations in expression of the ILC3-IL-22
axis-related and purine metabolic pathway genes in colon
biopsies from UC patients (Supplementary figure 3). These
findings collectively support a potential interaction between
the purine metabolic pathway, especially the ATP/NTPDase/
adenosine signaling pathway, and the ILC3-IL-22 axis in the
setting of intestinal inflammation. Given that both the
purinergic and ILC3-IL-22 pathways have been indicated to
regulate intestinal inflammation, these genetic results
prompted us to investigate whether the purinergic signaling
has a role in modulation of ILC3-IL-22 pathway in response
to gut epithelial injury.
NTPDase inhibition results in more severe intestinal
injury and reduction of mucosal ILC3s
To address the potential interaction between the NTPDase-
mediated purine metabolic pathway and the ILC3-IL-22
axis and its role in intestinal injury, we used the dextran-
sulfate sodium (DSS)-induced intestinal injury model
and pharmacologically inhibited the function of
NTPDases using a small molecule compound sodium
polyoxotungstate 1 (POM-1). POM-1 inhibits
phosphohydrolysis of ATP by selectively targeting
NTPDases, especially NTPDase1 and NTPDase3, both
overexpressed in human inflamed intestinal mucosa
(Figure 1b).35 It has been reported that global deficiency of
NTPDase1 or NTPDase3 resulted in exacerbation of DSS
colitis.9,36 DSS administration induced similar body weight
loss in both control and POM-1-treated mice. However,
POM-1 treatment led to more severe intestinal bleeding
and reduced mice general appearance, leading to
augmented colonic inflammation, evidenced by shortened
colon and more severe pathology compared to control
mice (Figure 2a–c). Mice treated with POM-1 in the
absence of DSS did not develop any sign of intestinal
inflammation (data not shown). Our results are in
agreement with a previous report showing that
administration of POM-1 enhanced extracellular ATP
levels in colons and worsened DSS-induced colitis while
administration of apyrase, an enzyme mediating ATP
degradation, ameliorates DSS-colitis.37 To gain insight into
the mechanisms driving NTPDase-dependent attenuation
of colonic damage, we analyzed adaptive and innate
lymphocytes in the colon by flow cytometry. Previous
studies have shown that epithelial damage (e.g. induced by
DSS) led to expansion and activation of RAR-related
orphan receptor gamma t (RORct)+ ILC3s, and that
deactivation of ILC3s reduced IL-22 production and
delayed the recovery from colitis.20 We thus investigated
the relationship between NTPDase inhibition and
intestinal ILC3s in the steady state and during colonic
inflammation. We found that in steady state, POM-1
treatment significantly reduced accumulation of
CD45+Lineage (Lin, CD3/B220/CD11c/CD11b/
NK1.1)CD90.2+RORct+ ILC3s, but not activated IL-22-
producing ILC3s, in the colon (Figure 2d, e and
Supplementary figure 4). In addition, POM-1 also
decreased colonic IL-22+CD3+ T cells as well as Foxp3+
Tregs (Figure 2e–g), the latter was in agreement with
previous findings showing that NTPDases (especially
CD39) are critical for Treg development and function.11
Administration of DSS did not change the numbers of
RORct+ ILC3s in the colon but increased colonic IL-22+
ILC3s by ~4-fold while colonic IL-22+CD3+ T cells were
not changed by DSS (Figure 2d, e, h, i). Co-administration
of POM-1 significantly prevented DSS-dependent increase
in IL-22+ ILC3s but did not affect any T-cell subsets
examined compared to that in mice treated with DSS and
vehicle control (Figure 2h–k), suggesting that ILC3s are
the main possible source of IL-22 produced in response to
acute gut damage and they are negatively correlated with
intestinal damage. DSS alone also increased accumulation
of colonic IL-17+CD3+ T cells and Foxp3+ Tregs, but these
T-cell subsets were not affected further by POM-1 co-
treatment (Figure 2f, g, j, k). These data indicate that
NTPDase-dependent protection against acute intestinal
injury is likely associated with IL-22-producing ILC3s.
To further study the involvement of non-T cells in
control of gut inflammation by NTPDases, we used the
DSS-induced colonic injury model in Rag1/ mice that
have no T and B cells. Similar to WT C57BL/6 mice,
POM-1 treatment increased the severity of DSS-induced
colitis in Rag1/ mice and shortened colon length
(Figure 2l, m). In these mice, POM-1 treatment again
reduced both the frequency and absolute number of
IL-22+ ILC3s in the colon (Figure 2n). Furthermore,
POM-1 treatment decreased IL-22 mean fluorescent
intensity (MFI) in ILC3s, suggesting an inhibitory effect
of POM-1 on IL-22 production from ILC3s at the
single-cell level (Figure 2n). Moreover, POM-1
treatment also decreased colonic ILC3 expression of
CD39, the key ENTPDase encoded by ENTPD1 gene
(Figure 2o). These results, together with results of the
downregulation of RORct and IL-22 expression in
ILC3s, further confirm our findings about gene
expression of the purinergic and ILC3/IL-22 pathways in
human colon biopsies.
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Figure 2. Inhibition of NTPDases exacerbates dextran-sulphate sodium (DSS)-induced intestinal damage, which is associated with reduction of IL-22-
producing ILC3s. Wild-type C57BL/6 mice were treated with 1.5% DSS (a–c, h–k) or not (d–g) in drinking water from Day 0 to Day 6 and
intreperitoneally (i.p.) injected with an NTPDase inhibitor POM-1 or PBS from Day 2 to Day 7 daily. (a) Disease activity index (DAI). (b) Representative
colons and colon length. (c) Representative H&E–stained images of mouse proximal colon samples. (d–g) Numbers of colonic lamina propria
CD45+LinCD90.2+RORct+ ILC3s (d), IL-22+ ILC3s and T cells (e), IL-17+CD3+ T and IL-17+CD3 non-T cells (f), and Foxp3+CD3+ Tregs (g) from mice
treated with PBS (n = 6) or POM-1 (n = 6) detected by flow cytometry. (h–k) Numbers of colonic lamina propria CD45+LinCD90.2+RORct+ ILC3s
(h), IL-22+ ILC3s and T cells (i), IL-17+CD3+ T and IL-17+CD3 non-T cells (j), and Foxp3+CD3+ Tregs (k) from mice treated with dextran-sulphate
sodium (DSS) plus PBS (n = 6) or POM-1 (n = 9) detected by flow cytometry. (l–o) Rag1/ mice were treated with 1.5% DSS in drinking water from
Day 0 to Day 5. POM-1 (n = 10) or PBS (n = 10) was injected into mice from Day 2 to Day 6 daily. (l) Disease activity index (DAI). (m) Colon length.
(n) Numbers of colonic LP IL-22+ ILC3s and mean fluorescent intensity (MFI) of IL-22. (o) Numbers of colonic LP CD39+RORct+ ILC3s. Data shown are
mean  s.d. pooled from two independent experiments. Each point represents one individual mouse. *P < 0.05; **P < 0.01; ***P < 0.001 by two-
way ANOVA with a post hoc Bonferroni’s multiple comparisons test (a, l) or a two-tailed unpaired Student’s t-test (b, d–k, m–o).
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ILC3 produced IL-22 mediates NTPDase control of
intestinal inflammation
Because IL-22 is critical for protection against intestinal
barrier damage and acceleration of the epithelial repair
post injury.22-26 We thus asked whether exacerbation of
colonic damage by NTPDase inhibition is a consequence
of the reduction of IL-22 production from colonic ILC3s.
To address this question, we treated Rag1/ mice with
DSS and POM-1, and a subgroup of mice were
administrated with recombinant mouse IL-22 (rIL-22).
Indeed, administration of rIL-22 ameliorated POM-1-
dependent augmentation of colitis disease activity
(Figure 3a), reversed the shortening of colon length
(Figure 3b) and reduced the infiltration of CD11b+Ly-
6G+ neutrophils and CD11b+Ly-6G macrophages in the
colon (Figure 3c). However, neither RORct+ ILC3s nor
endogenous IL-22 production in the colon were affected
by rIL-22 (Figure 3d). These results suggest that ILC3-
producing IL-22 is important for control of colitis.
ATP and adenosine reciprocally regulate IL-22
production from ILC3s in vitro
To investigate how NTPDase influences ILC3 activation,
we isolated small intestinal lamina propria leukocytes from
Rag1/ mice and cultured them with IL-23 in vitro. IL-23
induced IL-22 production from lamina propria leukocytes,
which was almost completely prevented by POM-1
(Figure 4a). Flow cytometric analysis confirmed that IL-22
was produced by CD45+LinCD90.2+RORct+ ILC3s in
response to IL-23 stimulation, and IL-22 production from
ILC3s were reduced by POM-1 (Figure 4b). Similarly,
POM-1 also reduced IL-22 production from spleen ILC3s
(Supplementary figure 5a, b).
Inhibition of NTPDases prevents eATP hydrolysis,
leading to increase in eATP levels and reduction of its
metabolites such as adenosine.6,7 We further investigated
the effects of eATP and adenosine on IL-22 production
from ILC3s. We used apyrase (which mimics NTPDases to
mediate ATP hydrolysis) and ATPcS (a non-hydrolyzed
ATP analogue) to modulate the levels of eATP. Increasing
eATP levels (e.g. by addition of ATPcS) diminished IL-22
production from ILC3s, while reducing eATP levels (e.g.
through apyrase-inducing ATP breakdown) increased
IL-22 production by either intestinal or splenic ILC3s
(Figure 4c, d and Supplementary figure 5c, d). Reducing
the levels of eATP also increased IL-22 MFI among IL-22+
ILC3s (Figure 4d). In contrast, activation of adenosine
receptor A2A by a selective agonist CGS21680 increased
ILC3 production of IL-22 in a concentration-dependent
manner (Figure 4e, f). This is in agreement with our
observation that ILC3s highly express the A2A gene
(encoded by Adora2a), rather than other adenosine
receptors (Supplementary figure 6). These results indicate
that the balance of eATP and adenosine, which is
controlled by NTPDases, reciprocally regulates IL-22
production from ILC3s.
DISCUSSION
Here, we demonstrate that NTPDases, the key enzymes in
the purine metabolic pathway, have a crucial role in
protection against intestinal injury through controlling the
balance between ATP and its metabolite adenosine that
reciprocally regulate ILC3 activation (Figure 5). These
findings are consistent with previous reports that ATP and
adenosine exacerbates and protects against gut
inflammation, respectively.37-40 Mice deficient in NTPDases
Figure 3. Exacerbation of intestinal damage by NTPDase inhibition is
rescued by exogenous IL-22. Rag1/ mice were treated with 1.5%
dextran-sulfate sodium (DSS) in drinking water from Day 0 to Day 5.
POM-1 was injected from Day 2 to Day 6 daily, and rIL-22 (n = 6) or
PBS (n = 6) was injected from Day 0 to Day 6 daily. (a) DAI. (b)
Colon length. (c) Numbers of colonic LP CD11b+Ly-6G+ neutrophils
(left), Ly-6G MFI (middle) and CD11b+Ly-6G macrophages (right)
determined by flow cytometry. (d) Numbers of colonic LP
CD45+LinCD90.2+RORct+ ILC3s (left) and IL-22+ ILC3s (right). Data
shown are mean  s.d. from one experiment. Each point represents
one individual mouse. *P < 0.05; **P < 0.01 by two-way ANOVA
with a post hoc Bonferroni’s multiple comparisons test (a) or a two-
tailed unpaired Student’s t-test (b-d). NS, not significant.
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have more severe DSS-induced colitis, and human ENTPD1
gene polymorphisms increased IBD susceptibility and also
affected the homeostasis of the immune system.9,36 Our
results indicate that these protective roles of NTPDases are
also likely to be mediated through modulating innate
immune responses (e.g. ILC3s) in addition to reported
mechanisms via regulation of the adaptive immune system
(e.g. Treg and Th17/Th1 cells).11-13
At the early stage of mucosal injury, damaged epithelial
cells and activated immune cells release ATP into the
microenvironment of mucosal tissue. As a damage-
associated molecular pattern, eATP can also trigger the
activation of the NLRP3 inflammasome and induce IL-8
and IL-1b production.41 Besides this effect, our work
indicates that increase in the levels of eATP can also
prevent ILC3 activation and subsequent IL-22 production.
ILC3s are the innate counterpart of Th17 cells, and both
types of cells share the lineage-determining transcription
factors (e.g. RORct), cytokine production profiles (e.g.
IL-22, IL-17) and surface markers (e.g. IL-23R, IL-1R,
CCR6).18 ATP has been shown to promote Th17 cell
development through indirect actions on antigen-
presenting cells,4 but our findings suggest that ATP can
also directly act on ILC3s to suppress their function and
IL-22 production.
Injury of the gut epithelium, e.g. induced by DSS, not
only increases colonic eATP levels37 but also upregulates
NTPDases such as CD39.42 During the course of mucosal
inflammation, increasing expression of NTPDases leads to
ATP breakdown and release of extracellular adenosine,
which has been implicated as an endogenous protective
reagent in IBD.43 A2A and A2B receptors were suggested
to contribute to the anti-inflammatory action of
adenosine.44-46 We found here that ILC3s express high
Figure 4. ATP and adenosine reciprocally regulate IL-22 production from ILC3s in vitro. (a, b) Concentrations of IL-22 in supernatants (a) and
percentages of IL-22+ ILC3s (b) of small intestinal lamina propria leukocytes (siLPLs) isolated from Rag1/ mice and cultured without or with
IL-23 plus POM-1 or not overnight (a) or for 4 h (b). (c, d) Concentrations of IL-22 in supernatants (c) and percentages of IL-22+ ILC3s (d) of LP
leukocytes isolated from small intestine of Rag1/ mice and then cultured with IL-23 plus Apyrase or ATPcS overnight (c) or for 4 h (d). (e, f)
Concentrations of IL-22 in supernatants (e) and percentages of IL-22+ ILC3s (f) of spleen cells isolated from Rag1/ mice and then cultured with
IL-23 plus indicated concentrations of an A2A receptor agonist CGS21680 overnight (e) or for 4 h (f). Numbers adjacent to outlined areas
indicate percent RORct+IL-22+ ILC3s. Data shown are mean  s.d., representative from two or more independent experiments. *P < 0.05,
**P < 0.01, ***P < 0.001; ****P < 0.0001 by one-way ANOVA with a post hoc Bonferroni’s multiple comparisons test.
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levels of A2A receptor, and activation of the A2A receptor
promotes IL-22 production from ILC3s. Consistently, gene
expression of A2A rather than other adenosine receptors
was upregulated in inflamed colons compared to control
colons in humans. As the A2A receptor dominantly
activates the cAMP signaling pathway,7 these results are
consistent with our previous findings that ILC3 activation
and IL-22 production were positively regulated by another
cAMP elevating reagent prostaglandin E2.
22 Therefore, both
downregulation of ATP signaling and upregulation of
adenosine signaling may contribute to NTPDase-dependent
enhancing IL-22 production from ILC3s, leading to
protection against intestinal inflammation.
In agreement with our findings that the ATP/
NTPDase/adenosine pathway modulates ILC3 activation
and acute colonic inflammation in mice, microarray
analysis showed striking alterations in gene expression of
the purine metabolic pathway in the inflamed colon from
patients with active UC. While downregulation of
nucleoside-diphosphate kinases (e.g. NME2, PCK1,
PCK2) and adenylate kinase (e.g. AK1, AK2, AK3)
suggests a debilitated ATP biosynthetic process,
upregulated expression of ALPL and NTPDases, especially
ENTPD1, indicates the acceleration of ATP/ADP
hydrolysis. These gene expression data suggest a
possibility of reduction of the levels of eATP and increase
of the levels of extracellular adenosine at the inflamed
sites, together contributing to resolution of inflammation.
Indeed, ATP levels were reduced in the intestine of
patients with IBD,47-49 and expression of the A2A
receptor was upregulated in inflamed colons. Studies have
shown that selective agonists for activation of the A2A
receptor reduced tissue damage in various animal models
of IBD.44,50 Our results provide new insights into how
alterations in purine metabolism in response to tissue
damage modulate the pathophysiology of IBD, that is,
through interaction with the ILC3-IL-22 pathway. Given
that drugs targeting the purinergic signaling for
gastrointestinal diseases are being developed and
accelerated toward testing in clinical trials,51,52 our
findings will help to clarify their therapeutic mechanisms.
Besides ILC3s, there are many other intestinal cells that
also express NTPDases including CD39 and CD73. Because
of the relatively rare cell number of ILC3s when compared to
other types of cells (e.g. epithelial cells, mononuclear
phagocytes and T lymphocytes) in the gut, it is unlikely that
CD39+ ILC3s are the main cells responsible to NTPDase-
mediated regulation of eATP breakdown into adenosine.
Therefore, IL-22 production from ILC3s is more likely
controlled by NTPDase expressed from other cells (e.g.
epithelial cells and mononuclear phagocytes), rather than
ILC3s themselves, in the gut. Further studies are required to
elucidate the effects of NTPDase-mediated eATP hydrolysis
on ILC3 function and modulation of IBD using cell type-
dependent CD39 conditional knockout animals. Even
though, the inverse correlation of colonic CD39+ ILC3
numbers and the intestinal inflammation severity indicates
that CD39 expression on ILC3s may be potentially used as a
biomarker for the IBD severity. Taken together, our work
demonstrates that the balance between ATP and adenosine
controlled by NTPDases regulates ILC3 cell behavior in the
context of gut inflammation, suggesting that a combinational
approach of using pharmacological inhibition of the ATP
signaling, acceleration of extracellular conversion of ATP to
adenosine and activation of the adenosine receptors
represents a potential approach to improve the development
of new therapeutic strategies against IBD.
METHODS
Mice
Wild-type C57BL/6 mice were purchased from Harlan UK.
C57BL/6 Rag1/ mice were bred and maintained under specific
pathogen-free conditions in accredited animal facilities at the
University of Edinburgh. Mice used in this study were sex- and
Figure 5. A proposed model for how the ATP/NTPDase/adenosine
axis regulates ILC3s during intestinal injury. In response to dextran-
sulphate sodium (DSS) stimulation, injured epithelial cells produce a
large amount of extracellular ATP, which targets on ILC3s by
inhibiting IL-22 production, leading to exacerbation of intestinal
barrier damage. Simultaneously, tissue damage also induces
expression of NTPDases (e.g. CD39 and CD73) by many types of cells
(e.g. epithelial cells, mononuclear phagocytes and T cells). NTPDases
in turn convert extracellular ATP into adenosine. Unlike ATP, however,
adenosine promotes IL-22 production and ILC3 activation through its
receptor A2A, and therefore serves to protect against intestinal
damage. NTPDases thus regulate ILC3 activation and gut injury by
modulating the balance of extracellular ATP and adenosine.
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age (8–12 weeks old)-matched. Mice were analyzed individually
and no mice were excluded from the analysis, with the exception
of exclusions due to technical errors in preparation of intestinal
lamina propria leukocytes. All animal experiments were
conducted in accordance with the UK Scientific Procedures Act
of 1986 and approved by the local ethical approval.
DSS colitis model
Treatment of DSS was performed on WT C57BL/6 or Rag1/
mice.22 Briefly, WT C57BL/6 or Rag1/ mice (8–9 weeks old at
the beginning of experiments) were given 1.5% (w/v) of dextran
sulfate sodium (DSS, MW 36–50 kDa, MP Biochemical) in
drinking water for 6 or 5 consecutive days, respectively, followed
by normal water for a further 2 days. POM-1 (Tocris Bioscience,
Bristol, UK) or PBS was injected intraperitoneally (i.p.) into
indicated mice (20 mg per kg body weight per day) daily for 6
(for WT C57BL/6 mice) or 5 (for Rag1/ mice) consecutive
days from Day 2 after the beginning of DSS treatment. 1 lg of
recombinant IL-22 (PeproTech) or PBS was injected i.p. into
indicated Rag1/ mice daily for 7 consecutive days from the
beginning of the experiments. Throughout the experimental
timeline, mice were weighed and scored daily for a disease
activity index (DAI) score to monitor colitis progression and
pathology. The DAI was scored additively using the following
parameters: body weight: 0 (no or <1% weight loss compared to
Day 0 body weight), 1 (1–5% weight loss), 2 (5–10% weight
loss), 3 (10–20% weight loss), and 4 (>20% weight loss);
bleeding: 0 (no bleeding), 1 (blood present in/on feces), 2
(visible blood in rectum), and 4 (visible blood on fur); stool
consistency: 0 (well formed/normal stool), 1 (pasty/semi-formed
stool), 2 (pasty stool with some blood), 3 (diarrhea that does not
adhere to anus), and 4 (diarrhea that does adhere to anus); and
general appearance: 0 (normal), 1 (piloerection only), 2
(piloerection and lethargy), and 4 (motionless, sickly, sunken-
eyed and ataxic). Mice were immediately culled if body weight
loss was <25%, or the total colitis score was 12 or higher, or if
their general appearance score was 4.
Histology
Colon samples were fixed with 10% neutral buffered formalin
solution (Sigma, Dorset, UK), embedded in paraffin, and
5 lm sections were used for staining with hematoxylin and
eosin (H&E). Sections were photographed using a digital
camera and white balance adjustment of entire images was
done using Photoshop.
Isolation of intestinal lamina propria cells
Small and large intestinal lamina propria (LP) cells were isolated
as described previously.22 In brief, mice were culled and their
small and large intestines were removed. After removing any
remaining fatty and mesenteric tissues, samples were cut open
longitudinally and any contents removed, washed with HBSS
buffer containing 2% FCS, and then cut into 0.5 cm pieces.
Intestines were shaken at 37°C for 15 min in HBSS and washed
twice. Intestines were then transferred into gentleMACS C tubes
(Miltenyi) digested in RPMI 1640 medium containing 10%
FCS, 1.25 mg mL1 collagenase IV (Roche) and 30 lg mL1
DNase-I (Roche) by shaking at 37°C for 30 min. Digested
tissues were homogenized by gentleMACS disassociator running
the programme m_intestine_01 and mashed through a 40-lm
cell strainer and flushed through HBSS containing 2% FCS.
After centrifugation, cells were resuspended in complete RPMI
1640 medium for counting, staining, culture and/or sorting.
In vitro cell culture
Intestinal LPLs or spleen cells were isolated from Rag1/ mice
and cultured in completed RPMI 1640 medium supplemented
with 10% FBS, 2-Mercaptoethanol (50 lmol L1, Gibco,
Waltham, MA, USA), L-glutamine (2 mmol L1, Gibco) and
antibiotics (Penicillin and Streptomycin, 100 U mL1, Gibco).
When indicated, recombinant IL-23 (20 ng mL1, eBioscience,
San Diego, CA, USA), POM-1 (2–50 lmol L1, Tocris
Bioscience), APCP (2–50 lmol L1), Apyrase (10 lmol L1,
Sigma), ATPcS (5–10 lmol L1, Sigma), and A2A agonist CGS
21680 (1–10 lmol L1, Merck Chemicals, Darmstadt,
Germany) and their respective vehicle control (i.e. DMSO or
dH2O) or combination of these reagents were added into cell
cultures. For detecting cytokines in supernatants, cells were
cultured for overnight, and for intracellular staining of IL-22,
cells were stimulated for 4 h in the presence of GolgiPlug (BD
Bioscience, San Jose, CA, USA). In vitro cell cultures were
performed in triplicate and repeated two or more times.
Cell staining and flow cytometry
For surface staining, cells were first stained with the Fixable
Viability Dye eFluor 780 on ice for 30 min to exclude dead
cells. After wash, cells were stained on ice for another 30 min
with indicated Abs including anti-mouse CD45 eFlour 450
(Clone 30-F11), CD3e PE, CD11c PE, CD11b PE, B220 PE
(clone RA3-6B2), CD90.2 FITC (Clone 30-H12), CD4 PerCP-
Cyanine5.5 or APC, CD39 PE-Cy7 (clone Duha59), CD11b
FITC and Ly-6G (Gr-1) APC (clone RB6-8C5). For
intracellular staining of IL-22, cells were stimulated with IL-23
(20 ng mL1) for 4 h in the presence of GolgiPlug (BD
Bioscience). After staining with surface markers, cells were
fixed by the Foxp3/Transcription Factor Fix and Staining
Buffer for 2 h or overnight and then stained with anti-human/
mouse IL-22 APC (clone IL22JOP) and anti-mouse ROR-ct
PerCP-eFluor710 (clone B2D) in the Perm/Wash Buffer on ice
for 1 h. All antibodies were purchased from eBioscience or
Biolegend. Flow cytometry was performed on the BD LSR
Fortessa (BD Bioscience) and analyzed by FlowJo software
(Tree Star).
Enzyme-linked immunosorbent assay (ELISA)
For detection of IL-22 levels in supernatants of cell cultures,
ELISA Ready-SET-Go! kits for mouse IL-22 (eBioscience)
were used according to the manufacturer’s instructions.
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Gene expression analysis of human colon biopsies
Gene transcription levels were measured by transcription
microarray in a study by Vanhove et al.27 on human colonic
mucosal biopsies with active UC (n = 74), inactive UC (n = 23)
or controls (n = 11). Raw microarray data were retrieved from
the Gene Expression Omnibus dataset GSE59071.27 After
normalization, we detected two outliers in the active UC samples,
which did not at all relate to any other samples and showed other
quality shortcomings, and thus we removed those two samples
prior to further analysis. Gene expression data were transformed
into Z-score values for presentation with comparisons by a
nonparametric Kruskal–Wallis test with post hoc Dunn’s multiple
comparisons test. Analysis of the dataset GSE11223 was described
previously.34 Gene expression data were transformed into Z-score
values by genes across samples for presentation. The list of human
Th17- or ILC3-related genes and IL-22 signaling (responsive)
genes were retrieved from previous reports.29-32
Statistics
Statistical significance between two groups was examined by a
Student’s t-test, while a one-way or two-way analysis of variance
(ANOVA) with post hoc Bonferroni’s multiple comparisons test
were used to evaluate multiple groups. Parametric or
nonparametric tests were chosen based on the normality and
variance of data distribution. Correlation analysis was calculated
by Pearson’s correlation coefficient (r). Statistical work was
performed using the Prism 6 software (GraphPad) and P < 0.05
was considered statistically significant.
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